Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
Companies to combine expertise in immunology and infectious diseases to accelerate development of promising new therapeutics for influenza.
-
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults.
-
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
ViiV Healthcare with Pfizer Inc. and Shionogi Limited as shareholders, announced today the submission of a sNDA to the US FDA
-
GSK announces results evaluating its investigational monoclonal antibody, otilimab, for the treatment of hospitalised adult patients with COVID-19
GSK today announce results from the phase 2 proof of concept OSCAR study with otilimab, an investigational anti-GM-CSF monoclonal antibody.
-
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021
16 sponsored abstracts from our diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options will be presented
-
Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
The independent DSMB has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature.
-
GSK makes landmark pricing agreement for rotavirus vaccine, Rotarix, for use with children living in humanitarian crises
GSK has committed to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism.
-
ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks
Long-term efficacy and safety data from phase IIIb ATLAS-2M study reinforce therapeutic potential of long-acting cabotegravir & rilpivirine
-
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.
-
Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19
Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Medicago/GSK announce Ph 3 trial start of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant.
-
GSK starts the first phase 3 study with a long-acting anti-IL-5 treatment for patients with severe asthma
GSK '294 is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function
-
GSK to highlight scientific research in ovarian and endometrial cancer at SGO 2021 Annual Meeting on Women’s Cancer
This research builds on the body of evidence supporting poly (ADP-ribose) polymerase (PARP) inhibitor use for maintenance treatment.
-
Half of parents surveyed either cancelled or delayed their child’s scheduled meningitis vaccination during the COVID-19 pandemic – GSK survey shows [1]
The Ipsos survey on behalf of GSK offers insight into the pandemic's impact on meningitis vaccinations over the last 12 months.
-
Moncef Slaoui Departs Galvani Bioelectronics Board of Directors
Moncef Slaoui has been terminated as Chair of the Galvani Board of Directors, effective immediately.
-
GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19
The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE trial.
-
Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19
In combination, the 2 monoclonal antibodies demonstrated 70% relative reduction in persistent high viral load at day 7 compared to placebo.
-
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
-
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19.
-
Advil to Reduce Plastic in Over 80 Million Bottles by 20% with New Sustainable Plastic Technology
Advil to Reduce Plastic in Over 80 Million Bottles by 20% with New Sustainable Plastic Technology
